Nls pharmaceutics announces exclusive option agreement to develop and commercialize next generation dual orexin agonist platform of aexon labs, inc.

The option agreement grants nls pharmaceutics ltd. the exclusive option to in-license all of aexon labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and all future indications exclusive option agreement accesses global rights to multiple highly selective orexin-1 / orexin-2 receptor agonists, unique compounds designed for specificity, acting multiple pathways involved in the pathophysiology of narcolepsy and other central disorders of hypersomnolence additional targets include cathepsin-h inhibition, sigma-1 receptor agonist, dat and net reuptake inhibition, addressing neurotransmission, neuroprotection and neuroinflammation first patent application filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric disorders including narcolepsy nls continues to strengthen its neuroscience pipeline in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence and neurodegenerative disorders franchise zÜrich, switzerland / accesswire / december 1, 2023 / nls pharmaceutics ltd.
NLSP Ratings Summary
NLSP Quant Ranking